Recently, second-generation antipsychotics (SGAs), olanzapine plus fluoxetine, quetiapine extended release and aripiprazole have clearly demonstrated efficacy in the treatment of MDD patients ...

There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD). Methods This open-label, pilot study was designed to investigate the efficacy ...

However, thanks to advances in understanding and treatment options, individuals diagnosed with MDD can find hope and support ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The projected winner: The drug that produces the best outcome at six months in the battle against depression ... more ...

agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder ...

SP-624 is also currently being studied in a large Phase 2b study in patients diagnosed with MDD, with efficacy in ... over placebo during a 4-week treatment period. In a post-hoc analysis, the ...

In a post-hoc analysis, the company found statistically significant improvement versus placebo consistent across both investigator and patient measures of MDD in female subjects, which was ...

About Alzamend Neuro Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BPD, MDD and PTSD. Our mission is to ...

Supernus (SUPN) announced data in a poster presentation at Psych Congress 2024 with new data from its exploratory open-label Phase 2a clinical ...

New research reveals that perimenopausal women are more than twice as likely to develop bipolar disorder for the first time.

Skrivo said the design references skateboarding ramps, which gives the collection a playful energy and distinguishable aesthetic. Each piece can be used as an independent item or combined to form ...